4314
D.G. Piotrowska, A.E. Wro´blewski / Tetrahedron 65 (2009) 4310–4315
C25H30NO4P: C, 68.32; H, 6.88; N, 3.19. Found: C, 68.09; H, 6.93; N,
3.33.
2.20 (dsp, JH3–H2¼8.1 Hz, JH3–Me¼6.5 Hz, 1H, CHCCP), 1.09 and 0.89
(2ꢂd, J¼6.5 Hz, 6H, CH3CCH3). 31P NMR (CDCl3)
¼23.04.
d
4.3. Dimethyl (1R,2S)-2-(N,N-dibenzylamino)-1-hydroxy-3,3-
dimethylbutylphosphonate (1R,2S)-5d
4.4.3.3. Dimethyl (1R,2S)-2-(N,N-dibenzylamino)-1-mesyloxy-3,3-
dimethylbutylphosphonate (1R,2S)-6d. 31P NMR (CDCl3)
d¼23.46.
A mixture of a crude (S)-N,N-dibenzyl-
after Swern oxidation of (S)-N,N-dibenzyl-
L
-tert-leucinal [obtained
4.4.4. Aziridinium mesylates (2S,3S)-7b–d
L
-tert-leucinol45 (0.530 g,
1.78 mmol)], dimethyl phosphite (0.163 mL, 1.78 mmol) and tri-
ethylamine (0.073 mL, 0.53 mmol) was left at room temperature for
60 h. The residue was chromatographed on a silica gel column with
chloroform–methanol (100:1, v/v), the appropriate fractions were
collected and recrystallised from chloroform–diethyl ether to give
4.4.4.1. (2S,3S)-1,1,2-Tribenzyl-3-(dimethoxyphosphoryl)aziridinium
mesylate (2S,3S)-7b. 1H NMR (CDCl3)
d
¼7.6–7.1 (m, 15H), 5.89 (dd,
JH2–P¼7.8 Hz, JH2–H3¼3.0 Hz, 1H, HCP), 5.35 (br d, J¼14.1 Hz, 1H,
PhHaCHN), 4.65 (br d, J¼14.1 Hz, 1H, PhHACHN), 4.25 (d, J¼14.1 Hz,
1H, PhHCHBN), 4.21 (dd, J¼14.1, 4.5 Hz, 1H, PhHCHbN), 4.06 (local-
ised by COSY) (m, HCCP), 3.91 and 3.85 (2ꢂd, J¼11.1 Hz, 6H,
CH3OPOCH3), 3.58 (d, J¼14.1 Hz, 2H, PhHCHN), overlapped by sig-
nals of major components (m, 2H, PhHaCHbCCP), 2.75 (s, 3H,
phosphonate (1R,2S)-5d (0.327 g, 45%) as colourless needles. Mp
20
133–134 ꢀC. [
a
]
ꢁ27.8 (c 1.0, CHCl3). IR (KBr) ¼3232, 2956, 1494,
n
D
1453, 1222, 1058, 1017, 745, 701 cmꢁ1. 1H NMR (CDCl3):
d
¼7.40–7.20
2
(m, 10H), 4.56 (dd, JH–P¼17.7 Hz, JH1–HO¼7.2 Hz, 1H, HCP), 4.30–
3.75 (vbr s, 2H, PhHCHN), 3.86 and 3.81 (2ꢂd, J¼10.2 Hz,
6H, CH3OPOCH3), 3.45 (br d, J¼13.0 Hz, 2H, PhHCHN), 2.94 (d,
3JH2–P¼12.6 Hz, 1H, HCCP), 2.45 (dd, JP–HO¼8.1 Hz, JH1–HO¼7.2 Hz,
CH3SO2). 13C NMR (CDCl3)
d
¼resonances of aromatic carbons are
overlapped by signals of major components, 58.60 (d, J¼2.2 Hz, C3),
57.70 (s, PhCH2N), 57.41 (d, J¼1.5 Hz, PhCH2N), 55.54 and 54.82
(2ꢂd, J¼6.9 Hz, CH3OPOCH3), 47.22 (d, J¼173.2 Hz, C2), 39.77, 31.80
1H, HO), 1.00 [s, 9H, (CH3)3C]. 13C NMR (CDCl3)
d¼139.67 (br s),
(s, CCCP). 31P NMR (CDCl3)
d¼13.97.
129.48 (br s), 128.16, 127.02, 68.43 (d, 1JCP¼150.9 Hz, C1), 64.81 (d,
J¼6.0 Hz, C2) 56.96 (br s, PhCH2N), 53.56 and 53.37 (2ꢂd, J¼7.5 Hz,
4.4.4.2. (2S,3S)-1,1-Dibenzyl-3-(dimethoxyphosphoryl)-2-isopropyl
aziridinium mesylate (2S,3S)-7c. 1H NMR (CDCl3)
¼7.75–7.65 (m,
2H), 7.60–7.45 (m, 6H), 7.43–7.32 (m, 2H), 5.66 (dd, JH2–H3
CH3OPOCH3), 36.99 (C3), 29.56. 31P NMR (CDCl3)
d¼28.28. Anal.
d
Calcd for C22H32NO4P: C, 65.17; H, 7.95; N, 3.45. Found: C, 65.34; H,
7.87; N, 3.45.
¼
8.3 Hz, JH2–P¼5.4 Hz, 1H, HCP), 5.12 (br d, J¼13.5 Hz, 1H, PhHaCHN),
4.61 (br d, J¼13.8 Hz, 1H, PhHACHN), 4.37 (d, J¼13.8 Hz, 1H,
PhHCHBN), 4.23 (dd, J¼13.5, 4.2 Hz, 1H, PhHCHbN), 4.09 and 3.89
0
4.4. Mesylation of 1-hydroxyphosphonates (general
procedures)
(2ꢂd, J¼11.1 Hz, 6H, CH3OPOCH3), 3.44 (ddd, JH3–P¼15.1 Hz, JH3–H3
¼
¼
0
0
10.7 Hz, JH3–H2¼8.3 Hz,1H, HCCP),2.83(dsp,JH3–H3 ¼10.7 Hz, JH3 –Me
4.4.1. In a toluene solution
6.7 Hz, 1H, HCCCP), 2.78 (s, 3H, CH3SO2), 1.31 and 0.81 (2ꢂd,
To
a
solution of 1-hydroxyphosphonate 5b, 5c or 5d
J¼6.7 Hz, 6H, CH3CCH3). 13C NMR (CDCl3)
¼131.10, 130.89, 130.80,
d
(0.051 mmol) in toluene (1 mL) triethylamine (0.036 mL,
0.255 mmol) was added followed by mesyl anhydride (0.027 g,
0.153 mmol) at 0 ꢀC. The reaction mixture was stirred at 0–5 ꢀC for
30 min, diluted with toluene (5 mL) and washed with cold water
(2ꢂ5 mL). The organic phase was dried over MgSO4. All volatiles
were removed in vacuo at room temperature, the residue was
dissolved in CDCl3 (0.7 mL) and the solution was immediately
analysed by 1H, 31P and 13C NMR spectroscopy.
130.45, 129.69, 129.55, 129.13, 128.94, 60.60 (d, J¼2.9 Hz, C3), 57.78
(s, PhCH2N), 57.15 (s, PhCH2N), 55.73 and 54.63 (2ꢂd, J¼6.9 Hz,
CH3OPOCH3), 48.49 (d, J¼176.0 Hz, C2), 39.56, 25.82 (d, J¼3.1 Hz,
CCCP), 20.53, 19.88. 31P NMR (CDCl3)
d
¼14.56.
4.4.4.3. (2S,3S)-1,1-Dibenzyl-2-(tert-butyl)-3-(dimethoxyphosphoryl)-
aziridinium mesylate (2S,3S)-7d. 1H NMR (CDCl3)
¼7.66 (d,
d
J¼7.6 Hz, 2H), 7.51 (t, J¼7.4 Hz, 2H), 7.48 (m, 2H), 7.46 (t, J¼7.1 Hz,
2H), 7.35 (d, J¼7.4 Hz, 2H), 5.26 (dd, JH2–H3¼9.4 Hz, JH2–P¼2.3 Hz,
1H, HCP), 4.74 (d, J¼13.6 Hz, 1H, PhHaCHN), 4.46 (d, J¼13.6 Hz, 1H,
PhHACHN), 4.40 (dd, J¼13.6, 4.5 Hz, 1H, PhHCHbN), 4.39 (d,
J¼13.6 Hz, 1H, PhHCHBN), 4.00 and 3.93 (2ꢂd, J¼11.1 Hz, 6H,
CH3OPOCH3), 3.57 (dd, JH3–P¼16.7 Hz, JH3–H2¼9.4 Hz, 1H, HCCP),
4.4.2. NMR tube experiments
To
a solution of 1-hydroxyphosphonate 5b, 5c or 5d
(0.026 mmol) in CDCl3 (0.7 mL) mesyl anhydride (0.077 mmol) was
added followed by injection of NEt3 (0.13 mmol). The progress of
mesylation was monitored by 1H and 31P NMR spectroscopy.
2.68 (s, 3H, CH3SO2),1.12 [s, 9H, (CH3)3C]. 13C NMR (CDCl3)
d¼131.14,
131.04, 130.58, 130.52, 129.70, 129.56, 129.14, 129.00, 63.02 (s, C3),
59.04 (s, PhCH2N), 58.84 (s, PhCH2N), 55.36 and 54.90 (2ꢂd,
J¼6.7 Hz, CH3OPOCH3), 48.53 (d, J¼178.5 Hz, C2), 39.42, 32.59 (s,
4.4.3. 1-O-Mesylates (1R,2S)-6b–d
4.4.3.1. Dimethyl (1R,2S)-2-(N,N-dibenzylamino)-1-mesyloxy-3-phe-
CCCP), 28.35 [s, (CH3)3C]. 31P NMR (CDCl3)
4.4.5. 2-O-Mesylates (1S,2R)-8b–d
d¼13.93.
nylpropylphosphonate (1R,2S)-6b. 1H NMR (CDCl3)
d
¼7.35–7.12 (m,
15H), 5.53 (dd, JH1–P¼11.5 Hz, JH1–H2¼1.0 Hz, 1H, HCP), 3.98 (d,
J¼14.1 Hz, 2H, PhHCHN), 3.73 and 3.71 (2ꢂd, J¼10.7 Hz, 6H, CH3O-
POCH3), 3.58 (d, J¼14.1 Hz, 2H, PhHCHN), 3.55 (ddd, JH2–H3b¼JH2–
4.4.5.1. Dimethyl (1S,2R)-1-(N,N-dibenzylamino)-2-mesyloxy-3-phe-
nylpropylphosphonate (1S,2R)-8b. 1H NMR (CDCl3)
¼7.35–7.10 (m,
¼7.2 Hz, JH2–H1¼1.0 Hz,1H, HCCP), 3.27 (s, 3H, CH3SO2), 3.15–3.03
d
H3a
(m, 2H, PhHaCHbCCP). 13C NMR (CDCl3)
d
¼139.23, 138.84, 129.68,
15H), 5.27 (dddd, JH2–P¼14.7 Hz, JH2–H3a¼7.2 Hz, JH2–H3b¼6.9 Hz,
JH1–H2¼3.3 Hz, 1H, HCCP), 4.08 (dd, J¼13.5, 3.0 Hz, 2H, PhHCHN),
3.76 and 3.60 (2ꢂd, J¼10.8 Hz, 6H, CH3OPOCH3), 3.68 (d, J¼13.5 Hz,
2H, PhHCHN), 3.50 (dd, JH3a–H3b¼13.8 Hz, JH2–H3a¼7.2 Hz, 1H,
PhHaCHbCCP), 3.45 (dd, JH1–P¼21.0 Hz, JH1–H2¼3.3 Hz, 1H, HCP), 3.16
(dd, JH3a–H3b¼13.8 Hz, JH2–H3b¼6.9 Hz, 1H, PhHaCHbCCP), 2.68 (s,
128.74,128.19,128.10,126.92,126.30, 74.43 (d, J¼160.3 Hz, C1), 59.11
(d, J¼4.5 Hz, C2), 53.65 (s, PhCH2N), 53.98 and 53.36 (2ꢂd, J¼7.5 Hz,
CH3OPOCH3), 40.07, 33.22 (s, C3). 31P NMR (CDCl3)
d¼21.74.
4.4.3.2. Dimethyl
(1R,2S)-2-(N,N-dibenzylamino)-1-mesyloxy-3-
¼7.30–7.10
methylbutylphosphonate (1R,2S)-6c. 1H NMR (CDCl3)
d
3H, CH3SO2). 13C NMR (CDCl3)
d
¼138.73, 136.28, 130.01, 129.30,
(m, 10H), 5.50 (dd, JH1–P¼13.5 Hz, JH1–H2¼1.5 Hz, 1H, HCP), 3.92 (d,
J¼13.8 Hz, 2H, PhHCHN), 3.79 and 3.69 (2ꢂd, J¼10.7 Hz, 6H,
CH3OPOCH3), 3.46 (d, J¼13.8 Hz, 2H, PhHCHN), 3.19 (s, 3H, CH3SO2),
2.96 (ddd, JH2–P¼10.8 Hz, JH2–H3¼8.1 Hz, JH2–H1¼1.2 Hz, 1H, HCCP),
128.99, 128.39, 127.34, 127.34, 81.92 (d, J¼7.7 Hz, C2), 57.26 (d,
J¼147.4 Hz, C1), 56.04 (d, J¼4.9 Hz, PhCH2N), 52.83 and 52.43 (2ꢂd,
J¼6.9 Hz, CH3OPOCH3), 39.46 (s, C3), 39.27. 31P NMR (CDCl3)
d¼26.18.